Aurigene Oncology Limited, a active public limited company, was established on 10 August 2001 in Bangalore, Karnataka, India. Engaging in biotechnology within the professional, scientific and technical sector, it holds CIN: U24239KA2001PLC029391. Registered under ROC Roc Bangalore. it is unlisted. It has an authorized capital of ₹240.00 Cr and a paid-up capital of ₹187.56 Cr.
Formerly known as Aurigene Discovery Technologies P Limited. It upholds a compliant status. Employing 479 professional, Its leadership includes Venkata Ramana Motupalli (Director), Satish Reddy Kallam (Director), Kumar Srinivasan (Director). Past directors included Vilanoor Sitaramanrao Suresh, Poh Kim Koh Bill, Venkateswarlu Akella. It holds no open charges and ₹6.59 Cr settled loans. Its latest AGM occurred on 26 July 2024, with the balance sheet filed on 31 March 2024. It is based at 39/49(P)Kiadb Industrial Area Electronics City Phase Ii, Bangalore, Karnataka, 560100.
U24239KA2001PLC029391
029391
10 August 2001
₹240.00 Cr
₹187.56 Cr
Roc Bangalore
Unlisted
Active
Explore comprehensive insights into Aurigene Oncology Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Venkata Ramana Motupalli | Director | 19 Oct 2023 | Current |
| Satish Reddy Kallam | Director | 10 Aug 2001 | Current |
| Kumar Srinivasan | Director | 01 Oct 2022 | Current |
| Shubhada Vivek Chiplunkar | Director | 01 Oct 2022 | Current |
| Venkateswara Prasad Gunupati | Director | 10 Aug 2001 | Current |
| Buggana Hariharnath | Director | 30 Mar 2015 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Company Secretary | 07 May 2008 | Past |
| Pramod Abcsdd | Director | 16 Jan 2012 | Past |
| Pramod Abcsdd | Director | 16 May 2008 | Past |
| Pramod Abcsdd | Additional Director | 22 Jul 2022 | Past |
| Pramod Abcsdd | Additional Director | 15 Jul 2015 | Past |
| Pramod Abcsdd | Director | 02 Jan 2013 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Aurigene Oncology Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 5.65% decrease. The company also saw a substantial fall in profitability, with a 49.64% decrease in profit. The company's net worth observed a substantial decline by a decrease of 10.71%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Aurigene Oncology had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹65,875,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 14 Sep 2011 | State Bank Of India | ₹6.50 Cr | Satisfied |
| 21 Oct 2005 | Icici Bank Limited | ₹0.88 M | Satisfied |
Explore comprehensive loan charge details -
Aurigene Oncology has a workforce of 479 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Aurigene Oncology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aurigene Oncology's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Aurigene Oncology Limited last Annual general meeting of members was held on 26 Jul 2024 as per latest MCA records. was completed.
Aurigene Oncology Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Bangalore. was recorded as a recent event.
Varun Kumar Challapalli was appointed as a Company Secretary was appointed as a Company Secretary on 20 Feb 2024 & has been associated with this company since 1 year 9 months . was recorded as a recent event.
Progress on Venkata Ramana Motupalli was appointed as a Director was appointed as a Director on 19 Oct 2023 & has been associated with this company since 2 years 1 month . was documented.
Progress on Kumar Srinivasan was appointed as a Director was appointed as a Director on 01 Oct 2022 & has been associated with this company since 3 years 2 months . was documented.
Progress on Shubhada Vivek Chiplunkar was appointed as a Director was appointed as a Director on 01 Oct 2022 & has been associated with this company since 3 years 2 months . was documented.
Me: Can't wait for the study results! Also me: But it's not until December 2018. #PatienceIsAVirtue #Phase1Data #StudyResults #December2018.
The CIN of Aurigene Oncology Limited is U24239KA2001PLC029391.
Aurigene Oncology Limited is headquartered at 39/49(P)Kiadb Industrial Area Electronics City Phase Ii, Bangalore, Karnataka, 560100.
Aurigene Oncology Limited was incorporated on 10 August 2001.
The current directors of Aurigene Oncology Limited are
The primary industry of Aurigene Oncology Limited is Professional, Scientific And Technical.
Aurigene Oncology Limited is unlisted.
The authorized capital of Aurigene Oncology Limited is ₹240.00 Cr, and the paid-up capital is ₹187.56 Cr.
The compliance status of Aurigene Oncology Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX